Ipratropium bromide HFA

Treatments in Respiratory Medicine

Volumn 4, Issue 3, 2005, Pages 215-220

  Wellington, Keri ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHLOROFLUOROCARBON; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUORINATED HYDROCARBON; IPRATROPIUM BROMIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; SALBUTAMOL; THEOPHYLLINE;

BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERABILITY; HUMAN; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; SPIROMETRY; TASTE DISORDER; XEROSTOMIA;

ADMINISTRATION, INHALATION; AEROSOL PROPELLANTS; BRONCHIAL SPASM; CHOLINERGIC ANTAGONISTS; HUMANS; IPRATROPIUM; LUNG DISEASES, OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 22544463989     PISSN: 11763450     EISSN: None     Source Type: Journal    
DOI: 10.2165/00151829-200504030-00006     Document Type: Review

References (12)

1. GOLD Scientific Committee. Global initiative for chronic obstructive lung disease - Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2004. Executive summary [online]. Available from URL: http://goldcopd.com/es2004clean.pdf [Accessed 2005 Feb 15]
2. National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004 Feb; 59 Suppl. 1: 1-232
3. Huchon G, Hofbauer P, Cannizzaro G, et al. Comparison of the safety of drug delivery via HFA- and CFC-metered dose inhalers in CAO. Eur Respir J 2000 Apr; 15 (4): 663-9
4. Forte R, Dibble C. The role of international environmental agreements in metered dose inhaler technology changes. J Allergy Clin Immunol 1999; 104 (6): S217-20
5. Brambilla G, Ganderton D, Garzia R, et al. Modulation of aerosol clouds produced by pressurised inhalation aerosols. Int J Pharm 1999 Sep 10; 186 (1): 53-61
6. American Thoracic Society and European Respiratory Society. Standards for the diagnosis and management of patients with COPD [online]. Available from URL: www.thoracic.org/COPD/pdf/copddoc.pdg [Accessed 2005 Feb 15]
7. Boehringer Ingelheim International GmbH. Atrovent® HFA (ipratropium bromide HFA) Inhalation Aerosol [online]. Available from URL: http://www.bidocs. com/renetnt:/Prescribing+Information/PIs/Atrovent+HFA/10003001_US_ 1.pdf?DMW_FORMAT=pdf [Accessed 2005 Mar 8]
8. Brazinsky SA, Lapidus RJ, Weiss LA, et al. One-year evaluation of the safety and efficacy of ipratropium bromide HFA and CFC inhalation aerosols in patients with chronic obstructive pulmonary disease. Clin Drug Invest 2003; 23 (3): 181-91
9. American Society of Health-System Pharmacists. Ipratropium bromide. AHFS Drug Information. 2005 ed. Bethesda (MD): American Society of Health-System Pharmacists, Inc., 2005: 1246-52
10. Friedman M, Littner M, Ghafouri M, et al. Ipratropium bromide HFA MDI 42 micrograms is clinically comparable to ipratropium bromide CFC MDI 42 micrograms in the treatment of COPD [abstract]. Am J Respir Crit Care Med 2001 Apr; 163 (5 Suppl. Pt 2): A278
11. Cuvelier A, Iacono P, Guemas E, et al. Ipratropium bromide MDI containing HFA propellant is as safe and effective as the CFC formulation: a dose confirmation study in patients with COPD [abstract]. Am J Respir Crit Care Med 1998 Mar; 157 (Suppl. Pt 2): A800
12. Taylor J, Kotch A, Rice K, et al. Ipratropium bromide hydrofluoroalkane inhalation aerosol is safe and effective in patients with COPD. Chest 2001 Oct; 120 (4): 1253-61